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Background: Diabetes mellitus (DM), one of the commonest worldwide metabolic 
conditions, recognized to persuade oxidant/antioxidant discrepancies. Sitagliptin is an 
oral anti-hyperglycemic remedy that blocks dipeptidyl peptidase 4 (DPP4). Rutin is a 
polyphenolic natural flavonoid which owns antioxidant and anti-proliferative activity. 
The aim of the present work is to elucidate the concomitant effect of Sitagliptin and rutin 
on the deleterious alterations in the liver of experimentally induced diabetes in rats.  
Materials and methods: 50 adult male albino rats, weighing 170-200 g were used. Rats 
were randomly divided into 5 groups (n=10).  Group 1 (control group), the other 4 groups 
(Groups II, III, IV and V) received a single i.p. injection of STZ, 65 mgKg-1 body weight 
to induce diabetes; group II (diabetic), group III (diabetic and rutin administered), group 
IV (diabetic and sitagliptin administered), and group V (diabetic with sitagliptin and rutin 
concomitantly administered).  H&E, masson trichrome, PAS, immune-histochemical; α-
smooth muscle actin (α-SMA), histomorphometric analysis, liver enzymes and  
oxidatants / anti-oxidatants; malondialdehyde (MDA)/ glutathione (GSH) and were done. 
Results: Distorted hepatic architecture, dilatation, congestion of sinusoids and central 
veins as well as cytoplasmic vacuolations were remarkable changes in the diabetic group. 
There was extravasation of blood, diffuse fibrous tissue formation, increase in the mean 
values of liver enzymes, oxidative markers and α-SMA expression in the same group. 
The aforementioned changes were ameliorated in groups III and IV. Concomitant 
administration of sitagliptin and rutin resulted in marked enhancement of these hepatic 
alterations. 
Conclusions: Combination of sitagliptin and rutin has an ameliorating effect on the 
hepatic deterioration induced by diabetes, which   is better than either sitagliptin or rutin 
alone. 




Diabetes mellitus is a metabolic syndrome categorized by elevated blood sugar 
levels and typical symptoms; polydipsia, polyuria and polyphagia [1]. Abnormal function 
of chief body organs comprising the liver can be a consequence of the upsurge of blood 
glucose levels [2]. The pivotal role of reactive oxygen species in the progress and 
exacerbation of DM impediments has been discussed for several epochs [3, 4]. Lipid 
peroxidation disturbs all lipid-encompassing structures in cells, resulting in 
cytopathological consequences [5].  
Rutin is a flavonoid compound that exists in various plants and possesses several 
pharmacological functions; blood glucose drop, insulin release regulator, dyslipidemic 
modifier. Moreover, it owns anti-inflammatory, anti-tumor as well as reactive oxygen 
species (ROS) attenuation possessions [6, 7, 8, 9].  
Many studies have revealed that rutin has a robust therapeutic influence on liver 
injury triggered by different reasons for instance; biliary obstruction and high fatty diet. 
Nevertheless, the mechanism of rutin in DM induced liver injury was not very distinct 
[10, 11]. Some researchers have exposed that the safety of rutin in diabetic liver can be 
attributed to its anti-inflammatory properties; impeding lipogenesis [12]. 
Sitagliptin is an antidiabetic prescription taken orally that blocks dipeptidyl 
peptidase 4 (DPP4). Suppression of DPP4 advances insulin sensitivity and hence, lessens 
blood glucose concentrations [13]. Sitagliptin definitely has been permitted by the FDA, 
Health Canada, as well as the European Commission as a solitary cure for the treatment 
of diabetes and it can be efficiently mutually administered with either metformin or 
glitazone (14, 15). 
The objective of this study is to elucidate the properties of Sitagliptin and rutin 
amalgamation on the pathological alterations of the liver of experimentally induced 
diabetes in rats.  
 
MATERIAL AND METHODS  
Chemicals 
Sterptozocin: (STZ) (Trade name Zanosar) was purchased from Sigma chemical 
company, St. Louis Missouri, USA, in the form of 1 g vials. The drug was dissolved in 
0.1 M sodium citrate (pH adjusted to 4.5). 
Sitagliptin: in the form of Januvia 100 tablet. Each tablet was ground and 
dissolved in 10 mL solution of 0.5% carboxymethyl cellulose (CMC), and afterwards 
shaken to obtain a suspension form (10 mg/mL). 
Rutin: was purchased from Sigma Chemical Co., St Louis, USA in the form of 
powder and dissolved in saline.   
Experimental animals 
50 adult male Sprague-dawley albino rats, weighing 170-200 g were used. They 
were retained in the animal house of Kasr Al-Aini Faculty of Medicine, Cairo University. 
The rats had free access to standard rat chow and water. They were maintained according 
to the standard guidelines of Institutional Animal Care and Use Committee, subsequent to 
Institutional Review Board approval. Rats were permitted to accustom for 2 weeks prior 
to the experiment.  
Rats were randomly divided into 5 groups (n=10).  
Group 1 (control) received an intraperitoneal (i.p.) injection of 0.1 mol/L sodium 
citrate buffer (pH 4.5).  
The other 4 groups (Groups II, III, IV, V) received a single i.p. injection of 
Sterptozocin (STZ), 65 mg/Kg-1 body weight [16], freshly dissolved in 0.1 M citrate 
buffer (pH 4.5). Diabetes mellitus was verified by measuring blood glucose levels (after 
overnight fast) with the use of glucose oxidase reagent strips (Lif3 scan, Milpitas, CA, 
USA). Rats with blood sugar level >250 mg/dl were used as the diabetic group. In order 
to monitor blood glucose levels, blood glucose was tested every week for 4 weeks. 
Group II (diabetic): diabetic rats received no treatment during the course of the 
study. Group III (diabetic + rutin ): diabetic rat received rutin at a dose of 10 mg/ kg/ 
day dissolved in saline orally for 4 weeks [11]. 
Group IV (diabetic + sitagliptin ): Diabetic rats received oral Sitagliptin at a 
dose of 100 mg/kg/day sitagliptin via gastric gavage for 4 weeks (17). 
Group V (diabetic + rutin+ sitagliptin ): Diabetic group receiving oral 
Sitagliptin  at a dose of 100 mg/kg/day concomitantly with  rutin at a dose of 10 mg/ kg/ 
day orally via gastric gavage for 4 weeks.   
All animals were clinically monitored and weighed on a weekly basis. After 4 
weeks a blood sample was withdrawn from the tail vein consuming fine heparinized 
capillary tube for assessing liver function. Formerly, the rats of each group were 
sacrificed utilizing an over dose of intraperitoneal phenobarbital sodium (40mg – kg). 
The rats were dissected. The liver of each animal was excised and prepared for light 
microscopic study. 
Liver specimens were fixed in formalin 10% dehydrated in ethyl alcohol, cleared 
in xylol and embedded in paraffin wax. Sections of five micrometers thickness were cut 
and mounted on glass slides. Other sections were mounted on +ve charged slides for 
immunohistochemistry.   
These sections were subjected to the following: 
I. Light microscopic study 
 H&E stain to study the changes in histo-pathological architecture. 
 Masson's trichrome stain to demonstrate collagen fibers. 
II. Histo-chemical study  
 Periodic acid Schiff reaction (PAS) to demonstrate the glycogen. The paraffin 
sections were dewaxed, rehydrated and then oxidized in 1% of periodic acid (5 min). 
Formerly, they were wash away with distilled water, pickled with Schiff’s reagent 
for 15 min, rinsed in tap water for 5–10 min, counterstained in haematoxylin, 
discerned in 1% acid-alcohol, cleansed in tap water, dehydrated in ascending degrees 
of alcohol, cleared in xylene, and mounted in Canada balsam. Glycogen and other 
reactive carbohydrates appeared magenta. 
III. Immune-histochemichal staining  
 Alpha smooth muscle actin (α-SMA) to evaluate the fibrosis processes (18). The 
segments from each paraffin block were incubated with primary antibody α-SMA 
antibody ((ab7817) 1:100). Next, the sections were incubated with Goat anti-Rabbit 
IgG H&L (HRP) (ab205718) for 20 min at 37°C. Each phase was tailed by 
satisfactorily wash with PBS. 
 
IV. Morphometric study: using Leica image analysis computer system (software Qwin 
500, switzerland), the following parameters were assessed:   
 Area % of collagen fibers in Masson's Trichrome  
 Mean optical density of PAS reaction in PAS  
 Area % of immune reaction of α SMA 
Stained sections were inspected by magnification x 400 and measured within a field of 
standard measuring frame. This was completed in 10 non overlapping microscopic fields 
of each specimen and their mean values were acquired.  
 
V. Biochemical study 
 Liver function assay  
Retro-orbital blood samples were extracted from each rat for valuation of liver enzymes. 
Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST) and Alanine Amino 
Transferase (ALT) enzymes levels were assessed using specific kits pro-vided by Bio-
diagnostic Company (Bio-diagnostic eka@lycos.com and info@bio-diagnostic.com). 
These measurements were done in the Biochemistry Department, Faculty of Medicine, 
Cairo University. 
 Assays of oxidative/antioxidative markers  
We measured MDA using a commercial kit (Biodiagnostic, Cairo, Egypt), according to 
the manufacturer’s instructions. Concisely, roughly 10-20 mg liver tissue was 
homogenized in 1 ml PBS, pH 7.0, utilizing a micropestle in a micro tube. At that point, 
20% (w/v) trichloroacetic acid was supplemented to the homogenate to precipitate the 
protein, and centrifuged at 12,000 x g for 15 min., afterwards, 0.8% thiobarbituric acid 
solution was added to the liver homogenate to precipitate the protein. After boiling for 10 
min in a water bath, the absorbance was measured at 405 nm using a spectrophotometer. 
The concentration of MDA was calculated per milli-gram protein using a standard curve. 
The standard curve was prepared as follows. We dissolved 25 μl 1,1,3,3 
tetraethoxypropane (TEP) in 100 ml water to attain a 1 mM stock solution. We organized 
a working standard by hydrolysis of 1 ml TEP stock solution in 50 ml 1% sulfuric acid 
and incubation for 2 h at room temperature. The resultant MDA 20 nmol/ ml standard 
was diluted with 1% sulfuric acid to yield the final concentrations of 10.5, 2.5, 1.25 and 
0.625 nmol/ml to prepare a standard curve for estimating total MDA. Then, 0.250 ml 
standard were mixed with 25 μl DNPH solution and incubated for 10 min. A 20 μl 
volume of the reaction mixture was injected directly onto HPLC system (Pilz et al., 
2000).  
GSH the antioxidant stress marker was measured using a commercial kit to detect 
glutathione (Biodiagnostic, Cairo, Egypt), according to the producer’s commands. The 
measurement was based on reduction of 5, 5 dithiobis-(2 nitrobenzoic acid), with reduced 
glutathione to create yellow compound. The reduced chromogen was directly 
proportional to GSH levels, and the ultimate reaction product was assayed 
spectrophotometrically by quantifying its absorbance at 405 nm.   
 
Statistical analysis  
The statistical package for the social science (SPSS) was used for data analysis. 
The data obtained from image analyzer were summarized as means and standard 
deviations and compared using one-way analysis of variance (ANOVA). P values C< 
0.05 was considered statistically significant, while P < 0.01 was considered statistically 
highly significant.  
 
RESULTS 
I. Light microscopic study 
Hematoxylin and Eosin results. Liver sections obtained from rats of the control 
group showed classic hepatic lobules consisting of intersecting plates of liver cells 
(hepatocyte) radiating outwards from a central vein to the periphery of the lobules. 
Narrow blood sinusoids were seen intervening between cords of hepatocyte (Fig. 1A). 
The portal area at the periphery of the lobules was seen formed of the bile ductule, a 
branch of portal vein with thin wall and wide lumen and branch of hepatic artery which 
appeared narrower in lumen and thicker in wall (Fig.1 B). The diabetic group (group II) 
revealed distortion of the parenchymal architecture. The hepatocytes exhibited marked 
pathologic affection where the cytoplasm displayed marked degree of cytoplasmic 
vacuolations.  The central vein was dilated and congested. There was marked congestion 
of portal vein with mononuclear cell infiltration in the portal area (Fig.1;C,D,E).The liver 
in H&E sections in the diabetic and rutin treated group (group III) revealed dilatation of 
central vein with vacuolated areas of degenerated hepatocytes (Fig. 1F). The diabetic and 
Sitagliptin treated group (group IV) exposed dilatation of central vein with small   
vacuolated areas between the hepatocytes. (Fig. 1G). Concomitant administration of 
rutin and Sitagliptin (group V) resulted in an apparently normal hepatic architecture as 
that of the control group apart from mild affections. Most hepatocytes were apparently 
normal with eosinophilic cytoplasm and rounded nuclei. There was mild dilatation of 
central vein (Fig. 1H). 
Masson's Trichrome Results. Histological examination of sections in the liver from 
rats of  group I showed minimal amount of collagen fibers in the form of thin layer of 
collagen fibers around the central vein and hepatic sinusoids (Fig. 2A). Group II 
exhibited an increase in the amount of dense collagen fibers around the portal tract and 
the blood sinusoids (Fig. 2B) and in between hepatocyte (Fig. 2B). Meanwhile, group 
III and IV displayed  moderate increase in the amount of dense collagen fibers around 
the portal tract and the blood sinusoids (Fig. 2C and 2D). On the other hand, group V 
showed mild increase in the amount of collagen fibers around the central vein and in the 
portal tract (Fig. 2E). 
 
Histo-chemical study 
PAS reaction results. In the control group the hepatocytic cytoplasm contained 
considerable amounts of glycogen and displayed strong positive PAS reaction in the form 
of small red granules filling the cytoplasm (Fig.3A).While, group III exposed very faint 
weak positive PAS reaction (Fig.3B). Meanwhile, group IV displayed weak positive and 
group IV showed moderate positive PAS reaction (Fig. 3D).However, group V revealed 
strong positive PAS reaction in the cytoplasm of hepatocyte (Fig. 3E). 
 
Immune-histochemical results  
Examination of the liver sections of group I revealed negative immunoreactivity of α-
SMA in the hepatocyte.  There was localized immunoreactivity around the central vein 
(Fig.4A). Group II and III showed strong positive immune-reactivity (Fig.4B and C). 
Group IV exposed moderate positive PAS reaction moderate positive immunoreactivity. 
(Fig. 4D). Nevertheless, Group V showed minimal positive immune-reactivity (Fig. 4E). 
 
Morphometric results 
 Statistical study of the mean area percentage of collagen fibers:  The mean area 
percentage of the collagen fibers of group   II, III and IV showed highly significant 
increase in its value compared with the corresponding control group. However, the 
mean value of the above mentioned parameter of group V was non- significant 
compared with the corresponding control group. The mean value of the area 
percentage of the collagen fibers of group II, III and IV increased significantly in 
comparison with group V (Tables 1 and Fig. 2F). 
 Statistical study of the mean optical density of PAS reaction: a significant increase 
in the optical density was found in group II and III in comparison with the 
corresponding control group. On the other hand, a significant decrease in the optical 
density was found in group IV and V in comparison with the group II (Table 1 and 
Fig. 3 F). 
 Statistical study of the area % of immune reaction of α SMA: The mean area % of 
α–SMA immune-positive cells showed no significant difference among the control 
group and group V. While diabetic group (group II) resulted in significant increase) in 
the mean area % of the α–SMA immunoreactivity as compared to groups I & V. 
(Table 1, Fig. 4 G). 
 
Biochemical assay 
Liver enzymes. Biochemical assay of the liver enzymes of the diabetic group 
revealed a marked increase in AST mean value which was statistically significant 
compared to the mean values of group I and groups IV, V. Meanwhile, treatment with 
sitagliptin and rutin in group V displayed a decrement in AST mean value which was 
statistically non-significant relevant to the corresponding values in the control group.  
Group II (diabetic group) showed marked increases in ALT mean value, which was 
statistically significant compared with the mean values of the control group and 
sitagliptin and rutin treated groups. Meanwhile, treatment with sitagliptin and rutin in 
group V showed reduction in ALT mean value which was insignificant in relation with 
the control group.  
The diabetic group showed a marked increase in ALP mean value which was 
statistically significant compared to the mean value of the control, and sitagliptin and 
rutin treated groups. On the other hand, treatment with sitagliptin and rutin in group III 
showed a reduction in ALP mean value which was statistically significant compared with 
diabetic group and non-significant compared with the value in the control group (Table 
2).  
 
Assay of oxidant and antioxidant markers  
Malondialdehyde (MDA). The liver homogenates of diabetic group demonstrated a 
marked upsurge in MDA mean value which was statistically significant compared with 
the mean value of the control group .Meanwhile, treatment with sitagliptin and rutin 
showed a reduction in MDA mean value compared with the same values in group II, and 
was statistically non-significant if compared with the values in the control group (Table 
3).  
Glutathione (GSH). The liver homogenates of group II demonstrated a marked 
decrease in GSH mean value which was statistically significant compared with the mean 
value of the control group. On the other hand, treatment with sitagliptin and rutin 
demonstrated an increase in the mean value, which was statistically non-significant 
compared with the value of the control group (Table 3). 
 
DISCUSSION 
In the present study, manifestations of the pathological effects of diabetes on the 
liver were observed. These histopathological effects include distorted hepatic 
architecture, dilatation and congestion of central veins, hepatocytic degeneration in the 
form of cytoplasmic vacuolation. These alterations in the liver were attributed to cellular 
necrosis and inflammation, which might be a result of amplified mitochondrial oxidative 
stress. The later stress could be a consequence of triglycerides metabolism and the 
establishment of free radicals in peroxisomes [19, 20]. The cytoplasmic vacoulation of 
hepatocytes is due to deprivation of the ATP energy stocks; prerequisite to sustain ionic 
and fluid homeostasis (21). The aforementioned mechanism results in reduced activity of 
the energy-dependent sodium pump plasma membrane. The failure of this active 
transportation system grounds sodium to cross the threshold and accumulate within the 
cells and potassium to blowout followed by gain of water, triggering cellular swelling 
[22]. In addition, high deliberations of ROS caused by suppressed oxidative 
phosphorylation predictably contribute to depletion of ATP [23]. 
Histomorphometric studies exhibited diminished PAS reaction (glycogen content) 
in the hepatocytes of the STZ-treated animals. Glycogen dislodgment in the cytoplasm of 
the hepatocytes might be due to the accumulation of lipid droplets [24].  
In the present study, fibrosis is an obvious manifestation in the diabetic group in 
the form of increased collagen fibers around central vein and portal area and increased 
expression of alpha smooth muscle actin. Beta-oxidation of fatty might occur due to 
inadequate insulin, and this leads to accumulation of hydrogen peroxide in tissues [25, 
26, and 27]. The existence of collagen in the presinusoidal spaces may distress blood 
supply to liver cells and reduce metabolic exchange, probably leading to hepatocellular 
dysfunction and necrosis [28]. The deposition of collagen in the liver can be accredited to 
to hepatic stellate cells (HSCs) that cause pathogenesis by liver damage-dependent 
activation. Activated HSCs discriminate into myofibroblasts (MFBs) [29]. MFBs exhibit 
a synthesis profile that lead to increase in their deposition in the extracellular matrix 
(ECM). This procedure helps them to proliferate, alters their morphology, and increases 
contractility by activating fiber formation of-smooth muscle actin (SMA). Then, this 
contributes to the constriction of sinusoidal blood flow and increases collagen fibers 
synthesis and release. 
In the existing research, tests for liver function were conducted to observe the 
effects of STZ-induced diabetes on the liver at 4 weeks after STZ treatment. Compared 
with control rats, levels of AST, ALT, and ALP were increased in diabetic rats. AST and 
ALT are both enzymes that are established principally in liver mitochondria [13]. If there 
is liver impairment the enzymes are released into the bloodstream after death of the liver 
cells [30]. Peculiarly, great levels of AST and ALT are pivotal indicators of hepatic 
injury [5].  
The present work revealed increment in MDA and decreased GSH in liver 
homogenates of diabetic rats. Recent studies have shown that the cause of DM advance 
and its complications is lipid peroxidase which leads to ROS formation (31). An increase 
in ROS generation and a decrease in antioxidant system activity result in an imbalance 
that leads to oxidative hassle [32]. The high blood sugar levels in diabetes lead to 
oxidative stress and fade the capacity of endogenous antioxidants. This is due to the 
production of many reducing sugars over both the glycolytic and polyol pathways [32]. 
In experimentally diabetic treated rats with oral intake of rutin (group III) or 
sitagliptin  (group IV), microscopic examination of the liver disclosed variable 
microscopic changes in the form of dilated congested central veins and cellular 
infiltrations at the region of portal tract and  some vacuolated areas.  The allocations of 
collagenous fibers were slightly decreased than the control group. 
In the current study co-administration of Sitagliptin and rutin in group V 
significantly improved the histological picture of the liver and the severity of liver 
damage was less as compared with the group treated with either Sitagliptin or rutin alone. 
Sitagliptin is an oral anti-diabetes drug known as an inhibitor of DPP-4 used to 
treat type II diabetes mellitus [33]. DPP-4 inhibition was proposed to reduce hepatic 
lipogenesis by several mechanisms; down-regulating the gene expression of sterol 
regulatory factor binding protein-1c (SREBP-1c), constraining fatty acid synthase, 
dropping the serum levels of VLDL and LDL cholesterol , subsequently decreased 
hepatic lipid accumulation and steatosis [10]. In addition, DPP-4 inhibition enhanced 
glycemic regulation; moreover, it modifies cholesterol synthesis, lipoproteins [34] and 
liver function enzymes (ALT, AST & ALP). Hence, all the previous mechanisms lead to 
amelioration of hepatic histo-pathological features in clinical trials of patients with type 
two diabetes [35]. 
Previous studies have publicized that rutin has a significant outcome on blood 
glucose control, and also has a very significant effect on the safety of liver cells [24, 29, 
36]. DM related hepatic cellular damage is meticulously interrelated to burdened free 
radicals, therefore rutin's antioxidant activity can shield the liver cells [7, 11] 
 
CONCLUSION AND RECOMMENDATIONS 
Concomitant administration of sitagliptin and rutin has an outstanding 
ameliorating role on diabetes-induced hepatic histolo-pathological and biochemical  
alterations. This is better than either rutin or sitagliptin alone. Therefore, the use of both 
sitagliptin and rutin give outstanding results in liver protection against diabetic changes, 
it is recommended furtherly to use rutin on higher doses to test its effect on diabetic 
induced and other hepatic injuries.   
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Table 1. Area % of collagen fibers, Optical density , and area % of α–SMA immune-
reaction in different experimental groups 
Groups Parameters 
Area % of 
collagen fibers  
Optical density  
 
Area % of α–SMA  
Group I (Control) 1.89 ± 0.16 0.812 ± 0.065 1.36± 0.12 
Group II (Diabetics) 15.74a ± 1.17 0.113 a ± 0.011 7.45 a ± 0.47 
Group III (Rutin) 10.99a,b ± 1.06 0.339 a,b ± 0.016 5.86 a,b ± 0.43 
Group IV 
(Sitagliptin) 
7.19 a,b± 0.49 0.565 a,b ± 0.031 3.44 a,b ± 0.21 
Group V (Rutin+ 
Sitagliptin) 
3.19b ± 0.21 0.765 b ± 0.041 1.44 b ± 0.11 
Data is shown as mean ± SEM, n = 10, Multiple comparisons were made using ANOVA one-way test 
followed by Tukey-Kramer as a post-hoc test. A: Certainly different from control p < 0.05. B: Significantly 
different from diabetic p < 0.05. 
 
 
Table 2. Mean values of liver enzymes in different experimental groups 
Groups AST 
Mean ± SD (IU/L) 
ALT 
Mean ± SD (IU/L) 
ALP 
Mean ± SD(IU/L) 
Group I (Control) 89.24 ±4.1  36.18 ±2.3 71.22 ±6.2  
Group II 
(Diabetics) 
152.16 a ±8.2  74.14 a ±3.4 162.32 a ±8.4  
Group III (Rutin) 125.99 a,b ± 1.06 59.39 a,b ± 0.016 115.86 a,b ± 0.43 
Group IV 
(Sitagliptin) 
112.15 a,b ± 0.49 51.55 a,b ± 0.031 89.44 a,b ± 0.21 
Group V (Rutin+ 
Sitagliptin) 
94.12 b ±4.1  40.18 b ±2.6  78.28 b ±9.2  
Data is shown as mean ± SD, n = 10, Multiple comparisons were made using ANOVA one-way test 
followed by Tukey-Kramer as a post-hoc test. A: Certainly different from control p < 0.05. B: Significantly 
different from diabetic p < 0.05. 
 
 
Table 3. Mean values of oxidative/ antioxidative markers in different experimental 
groups 
Groups MDA (nmol/g 
protein) 
GSH (μmol/g protein) 
Group I (Control) 18.62  ±2.4 0.28 ±0.02 
Group II (Diabetics) 42.18 a  ±3.6 0.12 a ±0.02 
Group III (Rutin) 30.99 a,b ± 1.06 0.19 a,b ± 0.016 
Group IV (Sitagliptin) 26,14 a,b ± 0.49 0.20 a,b ± 0.031 
Group V (Rutin+ Sitagliptin) 20.16 b ±1.8 0.22 b ±0.01 
Data is shown as mean ± SD, n = 10, Multiple comparisons were made using ANOVA one-way test 
followed by Tukey-Kramer as a post-hoc test. A: Certainly different from control p < 0.05. B: Significantly 
different from diabetic p < 0.05. 
 
 
Figure 1. A photomicrograph of sections of liver A, B (control), A: hepatic lobules and 
central vein (C); B: the portal triad consisting of branch of portal vein (P), bile ductule 
(B) and branch of hepatic artery (A). C , D & E (diabetic) C: loss of hepatic architecture 
with marked dilatation of central vein (C), cytoplasmic vacuolations in the hepatocytes 
(arrows) and vacuoles (V) in between the hepatocyte. D: dilatation of blood sinusoids 
(arrows) and degeneration of hepatocyte (arrow head), E: marked congestion of portal 
vein (P) with mononuclear cell infiltration (arrows). F (diabetic and rutin treated): 
marked dilatation of central vein (C) and vacuolated areas (V). G (diabetic and 
Sitagliptin treated): dilatation of central vein with minimal vacuolation (arrows).H 
(diabetic + rutin+ Sitagliptin treated): minimal dilatations of central vein. (H&E X400) 
 
Figure 2. Photomicrographs of sections of liver A (control): minimal amount of collagen 
deposition (arrow) around the central vein. B (Diabetic): increased collagen fibers 
deposition (arrows) in the portal area. Note the marked engorged portal vein (P). C 
(diabetic and rutin treated): increased collagen fibers deposition (arrows).  D (diabetic 
and Sitagliptin treated):  moderate collagen fibers deposition (arrows).  E (diabetic + rutin 
+ Sitagliptin treated): minimal collagen fibers deposition (arrows) F: area Percentage of 
collagen content in liver following administration of Rutin and/or Sitagliptin to diabetic 
Rats. *: Significantly different from control at p < 0.05. #: Noticeably different from 
diabetic p < 0.05. (Masson’s trichrome X 400) 
 
Figure 3. Photomicrographs of sections of liver A (control): strong positive PAS reaction 
of the hepatocyte around the central vein (C), B (Diabetic): weak positive PAS reaction 
of the hepatocyte. C (diabetic and rutin treated): moderate positive PAS reaction of the 
hepatocyte. D (diabetic and Sitagliptin treated): moderate positive PAS reaction of the 
hepatocyte. E (diabetic + rutin+ Sitagliptin treated): strong positive PAS reaction of the 
hepatocyte around the central vein (C). F: optical density in liver following 
administration of Rutin and/or Sitagliptin to diabetic Rat.*: Significantly different from 
control at p < 0.05. #: Noticeably different from diabetic p < 0.05 (PAS X400). 
 
Figure 4. Photomicrographs of sections of liver A (control): localized positive immune-
reactivity around central vein (arrows) and negative immune-reactivity in other parts, B 
& C (diabetic):  strong positive immune-reactivity. D (diabetic and rutin treated group):  
positive immune-reactivity. E (diabetic and Sitagliptin treated): moderate positive 
immunoreactivity. F (diabetic + rutin+ Sitagliptin treated): weak positive 
immunoreactivity  (arrows). G: area % of α–SMA in liver following administration of 
Rutin and/or Sitagliptin to diabetic Rats. *: Significantly different from control at p < 
0.05. #: Noticeably different from diabetic p < 0.05 (α-SMA X 400). 
 




